Logo
Menu
  • Who We Are
  • How We Invest
  • Our Portfolio
    • Abzena
    • Ixlayer
    • Kiniciti
    • PathAI
  • Blog
  • Careers
  • Contact
Driving Drug Development with Data Science

Driving Drug Development with Data Science

by Biospring | Apr 26, 2022 | Data Science, Digital Health, Drug Development, Drug Discovery, Janssen, Najat Khan

We were delighted to host a discussion with Najat Khan, PhD, Chief Data Science Officer and Global Head of Strategy and Operations, Janssen Research & Development (R&D), Johnson and Johnson. As the Chief Data Science Officer, Dr. Khan leads a team of 100+ data...
Proteomics 101

Proteomics 101

by Biospring | Apr 26, 2022 | DNA, Drug Development, Drug Discovery, Life Sciences Technology, Proteins, Proteome, Proteomics

Proteomics is the study of proteins (the proteome) in a cell, tissue, or organism. This emerging sector of the life sciences is helping scientists gain a deeper understanding of molecular biology. Proteins are large, complex molecules present in all living organisms....
The Opportunities for AI in Drug Discovery

The Opportunities for AI in Drug Discovery

by Biospring | Apr 26, 2022 | Artificial Intelligence, Data, Drug Discovery, Health Care, John Baldoni, Pharma

We recently hosted a discussion with Dr. John Baldoni, one of Biospring’s Operational Experts. He is the Co-Founder and Chief Scientific Officer of SaponiQx, a recently formed vaccine discovery and development company. He’s also the CEO of the Atom...
Synbio 101: A primer on the next big life sciences technology

Synbio 101: A primer on the next big life sciences technology

by Biospring | Apr 25, 2022 | DNA, Drug Development, Drug Discovery, Manufacturing, Pharma, Supply Chain, Sybio, Synthetic Biology

Synthetic biology (synbio) is a life sciences technology that is transforming a broad range of industries including agriculture, chemicals, food, and medicine. Synbio applies engineering principles to biology and uses genomics to “code” organisms to yield a desired...
Abzena update with Sven Lee

Abzena update with Sven Lee

by Biospring | Apr 25, 2022 | Abzena, Biologics, Biotech, CDMO, COVID-19, Drug Development, Drug Discovery, Drug Manufacturing, Pharma, Sven Lee

We shared an overview on Abzena following our investment in July. Over the past few months, Abzena has launched a new facility in San Diego and has made several executive hires. We recently spoke with Sven Lee, Chief Business Officer at Abzena, and he provided us with...

Recent Posts

  • Biospring Partners Welcomes Industry Executives To Its Advisory Board
  • Biomanufacturing: A Growing Field
  • Interview with Zach Weinberg
  • Driving Drug Development with Data Science
  • Proteomics 101

Recent Comments

No comments to show.

Newsletter

Thank you for subscribing!

Subscribe